Physician profile
Amanda Jo Stone
NPI 1821338252
$8,604.50
in general payments reported to CMS, 2019-2025
49 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,422 · 2022: $1,065 · 2023: $1,505 · 2024: $2,481 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,117.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,647.26 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $884.20 | 2021-2025 | |
| Glaxosmithkline, LLC. | $734.62 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $523.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $437.96 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $410.32 | 2021-2025 | |
| Axsome Therapeutics, INC. | $341.29 | 2023-2025 | Auvelity, Symbravo, Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.81 | 2021-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.01 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $276.19 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $248.58 | 2021-2025 | Freestyle Libre 3, Eterna |
| Astellas Pharma US INC | $235.52 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $220.32 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $175.48 | 2021-2024 | Xarelto, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $166.12 | 2021-2024 | Trintellix |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.